Tumor heterogeneity strongly affects the molecular mechanisms driving resistance to hormonal therapies in castration-resistant prostate cancer. Since the current use of available treatments can be optimized on the basis of the molecular profile of tumor, the present review focuses on genetic biomarkers in prostate cancer and their application to a personalized treatment.

Pharmacogenetics of androgen signaling in prostate cancer: focus on castration resistance and predictive biomarkers of response to treatment

Del Re, Marzia;Crucitta, Stefania;Restante, Giuliana;Rofi, Eleonora;Biasco, Elisa;Sbrana, Andrea;Coppi, Erika;Danesi, Romano
Ultimo
Writing – Review & Editing
2018-01-01

Abstract

Tumor heterogeneity strongly affects the molecular mechanisms driving resistance to hormonal therapies in castration-resistant prostate cancer. Since the current use of available treatments can be optimized on the basis of the molecular profile of tumor, the present review focuses on genetic biomarkers in prostate cancer and their application to a personalized treatment.
2018
Del Re, Marzia; Crucitta, Stefania; Restante, Giuliana; Rofi, Eleonora; Arrigoni, Elena; Biasco, Elisa; Sbrana, Andrea; Coppi, Erika; Galli, Luca; Bracarda, Sergio; Santini, Daniele; Danesi, Romano
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11568/916158
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 6
social impact